Skip to main
CAI

CAI (CAI) Stock Forecast & Price Target

CAI (CAI) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Caris Life Sciences is a promising investment opportunity due to its strong financial results, profitable growth plans, new product launches, and successful track record in commercializing tests. The company's partnership with Everlywell and success in their Caris Assure and cancer screening tests signal potential for further growth. While slower revenue growth and competition in the market may present challenges, Caris has a strong cash balance and a successful IPO that make it a favorable investment choice.

Bears say

Caris Life Sciences is facing significant headwinds in the competitive and rapidly evolving oncology testing market. Despite its impressive pipeline and market-leading tests like MI Cancer Seek, the company is facing challenges in gaining FDA approval and securing reimbursement for its new Chromoseq test and MRD testing offerings. Additionally, the recent launch of the Caris Detect MCED test into the highly competitive early cancer detection market may not yield significant revenue in the near term due to its high price point and lack of insurance coverage. Combined with potential litigation risks and the company's relatively small Achieve 1 study, which may limit confidence in the data, we maintain a negative outlook on Caris Life Sciences' stock.

CAI (CAI) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAI (CAI) Forecast

Analysts have given CAI (CAI) a Buy based on their latest research and market trends.

According to 8 analysts, CAI (CAI) has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAI (CAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.